Hepatic Steatosis carriers & HBsAg seroclearance

肝胆速递

Dig Dis Sci. 2012 Aug 18. [Epub ahead of print]
Clinical and Virological Characteristics Post HBsAg Seroclearance in Hepatitis B Virus Carriers With Hepatic Steatosis Versus Those Without.
Chu CM, Lin DY, Liaw YF.
Source

Liver Research Unit, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 199, Tung Hwa North Road, Taipei, 10591, Taiwan, [email protected].
Abstract
BACKGROUND:

It has been suggested hepatic steatosis contributes to seroclearance of hepatitis B surface antigen (HBsAg) in chronic hepatitis B virus (HBV) infection. Although HBsAg seroclearance generally confers favorable outcome, hepatic steatosis may account for progressive liver fibrosis and cirrhosis. Further studies are needed to compare clinical and virological characteristics post HBsAg seroclearance between subjects with hepatic steatosis and those without.
METHODS:

One-hundred and fifty-five HBsAg carriers with HBsAg seroclearance were enrolled. Subjects with moderate-severe hepatic steatosis as diagnosed by ultrasonography were designated as having hepatic steatosis.
RESULTS:

There were 69 subjects with hepatic steatosis and 86 without. Subjects with hepatic steatosis had significantly higher body mass index (BMI; 27.8 ± 3.5 vs. 23.0 ± 3.1, P < 0.001), were more likely to be male (78.3 vs. 63.9 %, P = 0.05), and were significantly younger at HBsAg seroclearance (48.7 ± 8.9 years vs. 53.4 ± 8.9 years, P = 0.001), than those without. The frequency of anti-HBsAg seroconversion (56.5 vs. 59.3 %, P = 0.72) and HBV viremia (20.3 vs. 15.1 %, P = 0.40) was not significantly different between subjects with and without hepatic steatosis, but the incidence of abnormal AST and ALT was significantly higher in the former (23.2 vs. 0 %, P < 0.0001; and 30.4 vs. 0 %, P < 0.0001, respectively), and progression to liver cirrhosis tended to be more likely in the former than in the latter (10.1 vs. 3.5 %, P = 0.09).
CONCLUSIONS:

In HBsAg carriers with increased body mass index, hepatic steatosis can accelerate HBsAg seroclearance by approximately 5 years. However, the beneficial effects of HBsAg seroclearance should be balanced against the harmful effects of hepatic steatosis.

肝胆速递

Dig Dis Sci科学。 2012年8月18日。 [EPUB的提前打印]
与那些没有与肝脂肪变性，临床和病毒学特征的乙肝病毒携带者的乙肝表面抗原转阴。
楚林DY，CM，廖YF。
源

肝脏胃肠病学和肝病学研究单位，部门，长庚医院，长庚大学医学院，199，敦化北路，台北，10591，台湾，[email protected]。
抽象
背景：

曾有人建议在慢性乙型肝炎病毒（HBV）感染B型肝炎表面抗原（HBsAg）转阴，肝脂肪变性的贡献。虽然乙肝表面抗原转阴通常赋予有利的结果可以解释为进展性肝纤维化和肝硬化，脂肪肝。还需要进一步研究，临床和病毒学特征后乙肝表面抗原转阴，肝脂肪变性和那些没有与主体之间的比较。
方法：

一百年和55 HBsAg携带者与乙肝表面抗原转阴的患者。被指定为肝脂肪变性的超声诊断为中重度肝细胞脂肪变性的主题。
结果：

与肝细胞脂肪变性分别为69名和86没有。与肝细胞脂肪变性的主题有显着较高的身体质量指数（BMI; 27.8±3.5与23.0±3.1，P <0.001），更有可能是男性（78.3％对63.9％，P = 0.05），并显着年轻的乙肝表面抗原转阴（48.7±8.9岁与53.4±8.9岁，P = 0.001），比那些没有。抗乙肝表面抗原血清学转换（56.5％对59.3％，P = 0.72）和HBV病毒血症（20.3％对15.1％，P = 0.40）的频率并没有显着不同的主体之间，无肝脂肪变，但AST异常的发病率和ALT显着较高，前者（23.2％比0％，P <0.0001; 30.4和0％，P <0.0001），并发展为肝硬化往往是在前者比后者更容易（10.1％对3.5％，P = 0.09）。
结论：

HBsAg携带者的身体质量指数增加，脂肪肝可以加速乙肝表面抗原转阴了约5年。然而，乙肝表面抗原转阴应该是平衡的有利影响，对脂肪肝的有害影响。

MP4

以下是朋友翻译：

但是需要的是：脂肪肝的不良影响 抵消S抗原阴的好处